Rockefeller Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Rockefeller Capital Management's GLUE Position: Q3 2026 in Review
Rockefeller Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 0.26% in Q3 2026, buying an estimated $240 and bringing the position to 5,309 shares worth $63.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3322.
Rockefeller Capital Management first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $128K in Q2 2026. 189 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Rockefeller Capital Management held 5,309 shares of Monte Rosa Therapeutics worth $63.3K as of Q3 2026.
- Rockefeller Capital Management bought 14 Monte Rosa Therapeutics shares in Q3 2026, an estimated $240.
- Monte Rosa Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3322 holding.
- Rockefeller Capital Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Rockefeller Capital Management's Monte Rosa Therapeutics position peaked at $128K in Q2 2026.
- 189 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.